Under the agreement, Teneovita will market and distribute Biocept's Target Selector liquid biopsy testing services to major cancer hospitals, individual oncology practices, and integrative oncology centers.
"With a focus on cancer solutions, Teneovita Medical is an ideal distributor to make our full range of liquid biopsy tests accessible to physicians and their patients across Canada," said Michael Nall, President and CEO of Biocept.
"In addition to the U.S. market, our liquid biopsy assays are now available in Israel, Mexico, the Philippines and Canada, and we continue to work toward expanding our market presence around the world."
"Adding cutting-edge liquid biopsy tests to our portfolio aligns with our focus on bringing innovative products to our hospital and physician customers," said Mark Elderfield, Chief Executive Officer of Teneovita Medical Innovations, Inc.
"Biocept's testing platform has the ability to rapidly and accurately detect the presence of actionable cancer-associated biomarkers without the need for an invasive tissue biopsy, and can provide critical information to help oncologists make treatment decisions and monitor patients. We are extremely pleased to offer this important service to our healthcare providers and their patients."
Teneovita Medical Innovations, Inc. is a healthcare solutions provider of innovative cancer care technologies.
Founded in 2011 and headquartered in Vancouver, British Columbia, Teneovita works in collaboration with accomplished medical professionals to drive impactful and sustainable improvements to healthcare operations and clinical performance.
Biocept is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.
The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer.
